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Objective: To identify follicle sizes on the day of trigger most likely to yield a mature 
oocyte following hCG, GnRH agonist (GnRHa), or kisspeptin during IVF treatment.
Design: Retrospective analysis to determine the size of follicles on day of trigger contrib-
uting most to the number of mature oocytes retrieved using generalized linear regression 
and random forest models applied to data from IVF cycles (2014–2017) in which either 
hCG, GnRHa, or kisspeptin trigger was used.
setting: HCG and GnRHa data were collected at My Duc Hospital, Ho Chi Minh City, 
Vietnam, and kisspeptin data were collected at Hammersmith Hospital, London, UK.
Patients: Four hundred and forty nine women aged 18–38 years with antral follicle counts 
4–87 were triggered with hCG (n = 161), GnRHa (n = 165), or kisspeptin (n = 173).
Main outcome measure: Follicle sizes on the day of trigger most likely to yield a mature 
oocyte.
results: Follicles 12–19 mm on the day of trigger contributed the most to the number of 
oocytes and mature oocytes retrieved. Comparing the tertile of patients with the highest 
proportion of follicles on the day of trigger 12–19 mm, with the tertile of patients with 
the lowest proportion within this size range, revealed increases of 4.7 mature oocytes 
for hCG (P < 0.0001) and 4.9 mature oocytes for GnRHa triggering (P < 0.01). Using 
simulated follicle size profiles of patients with 20 follicles on the day of trigger, our model 
predicts that the number of oocytes retrieved would increase from a mean 9.8 (95% 
prediction limit 9.3–10.3) to 14.8 (95% prediction limit 13.3–16.3) oocytes due to the 
difference in follicle size profile alone.
conclusion: Follicles 12–19 mm on the morning of trigger administration were most 
likely to yield a mature oocyte following hCG, GnRHa, or kisspeptin.
Keywords: follicle size, trigger, mature oocyte, iVF treatment, kisspeptin
inTrODUcTiOn
IVF treatment involves the administration of supra-physiological doses of follicle-stimulating 
hormone (FSH) to induce the growth of multiple ovarian follicles. Once ovarian follicles grow 
to an appropriate size, a trigger is administered to mature the oocytes in preparation for oocyte 
retrieval. It is widely accepted that ovarian follicles that are “too small” are less likely to respond 
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suitably to trigger administration and yield a mature oocyte (1). 
Furthermore, once ovarian follicles grow too large, follicles may 
contain oocytes that are “post-mature” and also not competent 
for fertilization (2). Most IVF centers will therefore, monitor fol-
licular size and administer the trigger of oocyte maturation once 
follicles are deemed to have grown to an appropriate size.
Relevant data exist as to the appropriate size of follicles on 
the day of oocyte retrieval that are most likely to yield an oocyte 
in both human and animals models (1). Overall, follicles of 
16–22 mm on the day of oocyte retrieval are more likely to con-
tain mature oocytes than smaller follicles, while larger follicles are 
more likely to contain post-mature oocytes (1). However, limited 
data exist to establish which follicle size on the day of trigger is 
most likely to yield a mature oocyte.
Data on follicle size on day of trigger with greatest propensity 
to yield oocytes are suggested by Hu and colleagues (3). They 
categorized Chinese women co-treated with a GnRH antagonist 
cycles by the proportion of follicles ≥10  mm which were also 
≥17 mm on the day of trigger; as low (30% ≥17 mm), middle 
(30–60% ≥17 mm), or high proportion (>60% ≥17 mm) (3). The 
investigators determined that the number of oocytes retrieved 
was greatest in those with a low proportion of follicles ≥17 mm 
(9.2 low vs 7.6 middle and 7.2 high) (3).
Importantly, knowledge of the size of follicles on day of 
trigger from which one could reasonably expect to retrieve 
a mature oocyte could enable the accurate determination of 
trigger efficacy. In 2007, Shapiro et  al. compared the efficacy 
of hCG and GnRH agonist (GnRHa) triggering (4), observing 
that GnRHa use resulted in significantly more oocytes retrieved 
(28.8) when compared with hCG (21.6) (4). However, patients 
receiving GnRHa had a greater number of follicles on the day 
of trigger (GnRHa 34.2 follicles; hCG 21.7 follicles) making it 
difficult to accurately compare trigger efficacy between the two 
groups (4). Thus, in their later work, Shapiro introduced the 
concept of an “oocyte yield,” whereby the number of oocytes 
collected is corrected for the number of follicles on the day of 
trigger (5). They reported mature oocyte yields (mature oocytes 
from follicles of ≥10  mm) of 63% after GnRHa (5). Other 
authors have reported both number of follicles ≥14  mm and 
the number of follicles ≥10 mm to allow the reader to account 
for different estimations of oocyte yield (6).
Kisspeptin is an endogenous neuropeptide that plays a key 
role in regulating the hypothalamo–pituitary–gonadal axis (7). 
Collectively, data from both animal models and humans have 
demonstrated that exogenous kisspeptin administration stimu-
lates endogenous GnRH release from the hypothalamus (7). 
Recently, kisspeptin has been used to induce oocyte maturation 
during IVF cycles with low rates of OHSS even in high risk 
women (8). Studies evaluating kisspeptin as a trigger of oocyte 
maturation used a denominator of follicles ≥14 mm on day of 
trigger to compare trigger efficacy following different doses 
and demonstrated a reasonable dose-response (9). Importantly, 
none of the denominators used to date are evidence-based, nor 
do they have an upper limit for follicle size to account for fol-
licles containing post-mature oocytes.
Therefore, we sought to determine the size of follicles on day 
of trigger that would be most likely to yield a mature oocyte. To 
identify the follicle sizes which were most likely to yield a mature 
oocyte, we analyzed follicle size data from 499 IVF cycles trig-
gered with either hCG, GnRHa, or kisspeptin.
MaTerials anD MeThODs
study Participants
Women were aged 18–38 years with a body mass index (BMI) 
18–29 kg/m2 and had antral follicle counts 4–87. GnRHa data 
were from a randomized controlled trial and hCG data from a 
case-series conducted at My Duc Hospital, Ho Chi Minh City, 
Vietnam (10). Kisspeptin data were obtained from patients 
undergoing clinical trials at Hammersmith Hospital, London 
(9, 11, 12).
GnRHa and hCG Triggers
Data for GnRHa were obtained from a randomized controlled 
trial of triptorelin dose 0.2–0.4 mg conducted at My Duc Hospital, 
Ho Chi Minh City, Vietnam. Data for hCG trigger were from a 
case-series also carried out at My Duc Hospital, Ho Chi Minh 
City, Vietnam. Inclusion criteria: age 18–38 years, BMI < 28 kg/
m2, normal ovarian reserve: AMH >  1.25  ng/ml (8.93  pmol/l) 
or AFC ≥6 (13). Exclusion criteria: polycystic ovary syndrome, 
chronic medical condition, participating in another clinical trial 
or use of LH/FSH preparations prior to the study. Patients did 
not receive hCG if there were more than 20 follicles of ≥14 mm 
on the day of trigger.
Kisspeptin Trigger
Data were obtained from patients undergoing clinical trials 
at Hammersmith Hospital, London. Inclusion criteria: aged 
18–34  years, BMI 18–29  kg/m2, early follicular FSH ≤12  IU/l, 
serum AMH ≥10  pmol/l (≥1.4  ng/ml), both ovaries intact. 
Exclusion criteria: moderate/severe endometriosis, poor ovarian 
response in a former IVF cycle [previous poor response (≤3 
oocytes retrieved on a previous IVF cycle), or ≥2 previous IVF 
treatment cycles].
study approvals
Data included in this manuscript were obtained from studies 
carried out in accordance with the recommendations of the local 
ethical boards listed below. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki and Good 
Clinical Practice.
Data from GnRHa triggered IVF cycles were obtained 
from a single-center randomized controlled trial conducted 
at My Duc Hospital, Ho Chi Minh City, Vietnam (10). The 
Institutional Review Board (IRB) reference number was 
NCKH/CGRH_01_2014 and ClinicalTrials.gov registration 
was NCT02208986. For the hCG case-series, the IRB reference 
number was NCKH/CGRH_09_2017, ethical approval reference 
number: 10/17/DD-BVMD and ClinicalTrials.gov Identifier: 
NCT03174691. For the kisspeptin trial ethical approval was 
granted by the Hammersmith and Queen Charlotte’s Research 
Ethics Committee, London, UK (reference: 10/H0707/2), under-
taken at the IVF Unit at Hammersmith Hospital under a license 
from the UK Human Fertilization and Embryology Authority 
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(9, 11, 12) and registered on the National Institutes of Health 
Clinical Trials database (NCT01667406).
iVF Protocol
Full details of the IVF protocols used for the GnRHa study (10) 
and the kisspeptin study (9, 11, 12) have previously been reported. 
In short, all IVF cycles were conducted using GnRH antagonist 
co-treatment and the trigger was administered once two to three 
follicles reached 17–18  mm in diameter. All follicles that were 
visible on ultrasound and ≥8  mm in diameter were aspirated 
at oocyte retrieval. Flushing was not conducted in GnRHa or 
hCG-triggered cycles. Flushing was occasionally conducted in 
kisspeptin-triggered cycles, although the literature suggests that 
this is unlikely to have impacted the number of oocytes retrieved 
(14, 15).
Patients triggered with GnRHa were stimulated, using a depot 
injection of 100–150 IU of corifollitropin alfa (Elonva; Merck 
Sharp & Dohme, UK) from cycle day 2, followed by co-treatment 
with ganirelix (Merck Sharp & Dohme B.V., Germany) (starting 
on day 5 after stimulation) and follitropin-β. The corifollitropin 
alfa dose used for stimulation was either 100 or 150 µg, depending 
on body weight, and the corresponding follitropin-β dose was 
150 or 200  IU/day, starting from day 8 of simulation until the 
day of triggering. Patients triggered with hCG were stimulated 
with follitropin-β daily (dose of 150–300 IU based on AMH level, 
AFC, age, history of previous response). The cycles were part of 
research conducted to study the endocrine profiles following trig-
gering. The trigger (either recombinant hCG 250 µg equivalent 
to 6,500 IU, or GnRHa triptorelin 0.2–0.4 mg) was administered 
as soon as two follicles reached a size of ≥17 mm. Fresh embryo 
transfer was not carried out in GnRHa- or hCG-triggered cycles.
For kisspeptin-triggered cycles, recombinant FSH (112.5–
150 IU Gonal F, Merck Serono, Geneva, Switzerland) was used 
to induce follicular growth and the GnRH antagonist cetrorelix 
(0.25 mg, Cetrotide, Merck Serono, UK) was administered from 
day 5 or 6. The trigger kisspeptin-54 (6.4–12.8 nmol/kg as a single 
subcutaneous bolus or 19.2 nmol/kg as a split bolus over 10 h, 
Bachem Holding AG, Bubendorf, Switzerland) was administered 
once three follicles reached ≥18 mm in diameter (9, 11, 12).
sizing Follicles on Day of Trigger
All patients included had a final ultrasound scan to assess follicle 
sizes on the morning of trigger. Sizing follicles was carried out 
during ultrasound assessment. For hCG and GnRHa triggered 
cycles, follicle size was assessed by transvaginal ultrasound 
(7.5 MHz probe) conducted by two dedicated ultrasonographers 
who have more than 10  years of follicle tracking, with a high 
degree of inter-observer correlation. For kisspeptin-triggered 
cycles, transvaginal ultrasonographic measurement (Toshiba 
Xario Prime, Crawley, UK) of follicle size was conducted by 
up to nine experienced IVF physicians/ultrasonographers at 
Hammersmith IVF unit over the 3-year study period.
statistical analysis
Analysis was performed in three stages. Combinations of follicle 
sizes were calculated, e.g., number of follicles 8, 8–9, 8–10, 8–11, 
etc. This was repeated from a baseline of 9  mm, then 10  mm, 
and so on such that every possible category of follicular size was 
derived. Initially, standard linear regression of number of follicles 
of different size categories on day of trigger and outcomes (num-
ber of mature oocytes collected) was performed. This involved 
fitting linear models that identify the coefficient of determination 
(r2) between the number of follicles within a certain size range 
and the number of mature oocytes retrieved. The coefficient of 
determination describes the variability in the number of mature 
oocytes retrieved by the number of follicles within each follicle 
size range around a linear relationship. This provided initial con-
firmation that the number of follicles of different size ranges was 
associated with the number of mature oocytes retrieved following 
each trigger.
However, a simple linear model compares the number of fol-
licles in each size category with the number of mature oocytes 
retrieved in isolation. Furthermore, simple linear models are 
susceptible to “autocorrelation,” whereby the number of follicles 
in one size category may also be included in other size categories. 
Hence, the more robust approach of generalized linear regression 
was used (16), allowing identification of the follicle size on the 
day of trigger with the greatest contribution to the number of 
mature oocytes retrieved, when compared with all other follicle 
size categories.
We used a third approach termed “random forest model,” 
which is a type of “ensemble modeling” utilizing modern 
machine learning technology (17). It is based on the formation 
of numerous decision trees to predict an outcome variable (in 
this case number of mature oocytes). Random forest models can 
be advantageous over generalized linear regression models if the 
number of outcome variables is comparatively low compared 
with the number of predictor variables. Random forest models 
also make no assumptions regarding linearity or parametric 
distributions in the data analyzed (and thus are less reliant on 
appropriate data transformation) and promote model variance 
by repeated sampling of the data. Hence, this method will more 
accurately return the follicle sizes with the greatest overall 
contribution to the number of mature oocytes retrieved. In our 
analysis 5,000 regression trees were produced, each derived using 
boot-strapped data (i.e., datasets of the same size as the entire 
data, but produced by random sampling with replacement), and 
the associations of number of follicles of different sizes with the 
number of mature oocytes were averaged across these models. 
More than one statistical approach was used to increase confi-
dence that the data allowed accurate determination of optimal 
follicle size on day of trigger.
Statistical analysis was performed using R version 3.3.1; random 
forest models were derived using the randomForest pckage, and 
validated using the cforest package, which is designed to identify 
and correct for potential autocorrelations in the data used.
To quantify the follicle size profile benefit on the number of 
oocytes and mature oocytes retrieved for the subjects within our 
data set, we compared patients with a lesser proportion (<70%) of 
follicles within the follicle size range determined above to patients 
with all (100%) of their follicles within that follicle size range. To 
estimate the potential impact of follicle size profile, we simulated 
patients with varying follicle profiles and calculated the differ-
ences in the number of mature oocytes collected.
Table 1 | Baseline characteristics.
Trigger
hcg (N = 161) gnrha (N = 165) Kisspeptin (N = 173) P-value
Age (years) 32.3 ± 3.2 27.0 ± 4.3 30.5 ± 2.8 P < 0.001
Ethnicity Southeast Asian 100% Southeast Asian 100% Caucasian 62.6%
South Asian 28.2%
Afro-Caribbean 4.6%
Other 4.6%
P < 0.001
Weight (kg) 50.3 ± 5.7 51.3 ± 7.4 64.4 ± 9.4 P < 0.001
Body mass index (BMI) (kg/m2) 20.5 ± 2.1 20.8 ± 2.7 24.2 ± 3.2 P < 0.001
Serum AMH (ng/ml) 4.2 (26, 5.9) 6.4 (4.6, 9.4) 6.1 (3.5, 9.5) P < 0.001
Antral follicle count 7 (5, 10) 17 (13, 24) 31 (25, 44) P < 0.001
Number of follicles on day of trigger 14 (11, 16) 17 (13, 24) 27 (21, 39) P < 0.001
Cumulative dose of recombinant follicle-stimulating hormone (IU)a 2,400 (2,025, 2,700) 900 (700, 1,300) 1,750 (1,388, 4,225) P < 0.001
Parametric variables are presented as mean ± SD while non-parametric are presented as median (interquartile range).
aPatients triggered with hCG were stimulated using daily follitropin-β (150–300 IU daily), whereas patients triggered with GnRH agonist (GnRHa) received a depot injection of 
corifollitropin alfa (Elonva) followed by daily follitropin-β. Patients triggered with kisspeptin received a starting daily injection of corifollitropin alfa (Gonal F) of 112.5–150 IU. Patients 
who received GnRHa or kisspeptin had higher AMH levels and more follicles on the day of trigger. Patients who received hCG or GnRHa were from Southeast Asia with lower 
weight/BMI than patients who received kisspeptin in UK. Groups with continuous variables were compared by Kruskal–Wallis test and categorical variables by χ2 test.
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resUlTs
Baseline characteristics are presented in Table 1, which have in 
part previously been reported (9–12).
Follicle size on Day of Trigger With 
greatest contribution to the number of 
Oocytes retrieved—simple linear 
regression analysis
First-pass analysis using simple linear regression of the number 
of oocytes retrieved vs the number of follicles on day of trigger 
in each category of follicle size determined that the highest coef-
ficient of determination to be at follicle size category 12–17 mm 
for hCG r2 0.433 (P < 0.0001); 10–14 mm for GnRHa r2 0.512 
(P < 0.0001); and 7–18 mm for kisspeptin r2 0.246 (P < 0.0001).
Simple linear regression of number of mature oocytes vs num-
ber of follicles in each category of follicle size determined that the 
highest coefficient of determination to be at follicle size category 
12–17 mm for hCG r2 0.374 (P < 0.0001); 10–15 mm for GnRHa r2 
0.573 (P < 0.0001); 7–20 mm for kisspeptin r2 0.179 (P < 0.0001).
A further subset of patients triggered with kisspeptin had 
their final follicle monitoring scan on the day prior to the day of 
trigger administration (n = 62). For these patients, the highest 
coefficient of determination for the number of oocytes retrieved 
was for follicle size category 9–14 mm r2 0.478 (P < 0.0001), and 
for the number of mature oocytes also for follicle size category 
9–14 mm r2 0.444 (P < 0.0001).
Follicle size on Day of Trigger With 
greatest contribution to the number of 
Oocytes retrieved—generalized linear 
regression Model and random Forest 
Model
A generalized linear regression model was used to determine the 
sizes of follicles on the day of trigger contributing most to the 
number of oocytes and mature oocytes retrieved (see Table 2). 
For both hCG and GnRHa, follicle sizes of 12–19 mm had the 
greatest contributions to the number of oocytes and mature 
oocytes retrieved (see Table 2). For kisspeptin, the data were less 
clear, but significant follicle size categories were in a similar size 
range.
The regression coefficient (r2) for the generalized linear 
regression model to determine the number of oocytes 
retrieved for hCG was 0.49 for oocytes and 0.44 for number 
of mature oocytes retrieved. The regression coefficient (r2) 
for the generalized linear regression model to determine the 
number of oocytes retrieved for GnRHa was 0.56 for oocytes 
and 0.64 for number of mature oocytes retrieved. The regres-
sion coefficient (r2) for the generalized linear regression model 
to determine the number of oocytes retrieved for kisspeptin 
was 0.50 for oocytes and 0.39 for number of mature oocytes 
retrieved.
Results from random forest analysis were consistent with the 
generalized linear regression model suggesting that follicle sizes 
of 12–19  mm on the day of trigger had the greatest predictive 
importance for the number of oocytes and number of mature 
oocytes retrieved (see Table 3).
Equivalent results for the relationship between follicle sizes on 
day of trigger and the number of embryos and grade 1 blastocysts 
are presented in Table 4 (generalized linear model) and Table 5 
(random forest model).
impact of the Proportion of Follicles 
Within the size range 12–19 mm on the 
number of Oocytes retrieved
Comparing the 50% of patients with the highest proportion 
of their follicles within the size range 12–19 mm with the 50% 
with the lowest proportions in this range revealed an increase 
in the number of oocytes of 3.6 oocytes and 3.3 mature oocytes 
(P <  0.0001) for hCG and 3.9 oocytes and 2.5 mature oocytes 
(P <  0.01) for GnRHa triggering. Importantly, there was not a 
Table 3 | Model importance factors (random forest) for follicle diameter in determining number of oocytes and number of mature oocytes.
Follicle 
diameter (mm)
hcg gnrh agonist (gnrha) Kisspeptin hcg gnrha Kisspeptin
Oocytes Mature oocytes
Model importance 
factor
Model importance  
factor
Model importance 
factor
Model importance 
factor
Model importance 
factor
Model importance 
factor
8 18.9 1.3 177.3 25.8 0.7 241.4
9 42.2 0.2 102.8 48.0 0.3 107.0
10 41.4 19.8 66.1 34.7 23.3 77.5
11 38.7 54.8 103.4 35.9 53.2 88.5
12 104.9 158.9 88.8 113.5 150.4 84.9
13 148.9 109.8 172.6 197.8 66.1 143.7
14 296.3 340.7 197.1 239.8 340.9 110.7
15 207.8 335.9 58.8 215.7 360.0 77.6
16 190.7 172.8 222.6 187.2 154.3 312.0
17 255.8 287.5 220.3 256.3 312.8 214.9
18 189.5 132.4 107.5 186.5 124.4 77.0
19 111.2 109.4 41.2 102.4 151.7 47.6
20 71.6 46.8 51.9 92.3 36.8 42.9
21 28.2 20.0 29.5 26.3 16.6 30.9
22 30.6 7.8 19.4 22.5 7.5 32.7
23 12.0 1.9 23.5 7.1 1.0 19.7
24 11.3 0.0 22.4 8.3 0.0 18.8
25 0.0 0.0 15.4 0.0 0.0 18.7
Model importance factors are the increases in node purity given by each follicle diameter averaged over 5,000 classification trees, each derived using bootstrap samples from the 
study data. Values over 100 (in bold) denote follicle diameters that are consistently important as predictors across multiple models, and hence strengthen the P-value results given in 
Table 2 which could result from a chance configuration of the study data.
Table 2 | Generalized linear model of the number of oocytes and the number of mature oocytes retrieved by follicle diameter.
Follicle diameter (mm) hcg gnrh agonist (gnrha) Kisspeptin hcg gnrha Kisspeptin
Oocytes Mature oocytes
P-value P-value P-value P-value P-value P-value
8 0.8 0.5 0.2 0.5 0.5 0.05*
9 0.2 0.7 0.1 0.1 0.8 0.2
10 0.1 0.2 0.9 0.2 0.1 0.9
11 0.3 0.02* 0.4 0.2 0.009** 0.6
12 0.02* <0.0001*** 0.03* 0.1 <0.0001*** 0.04*
13 <0.0001*** <0.0001*** 0.2 <0.0001*** <0.0001*** 0.5
14 <0.0001*** <0.0001*** 0.02* <0.0001*** <0.0001*** 0.5
15 <0.0001*** <0.0001*** 0.8 <0.0001*** <0.0001*** 0.7
16 <0.0001*** <0.0001*** 0.9 <0.0001*** <0.0001*** 0.4
17 <0.0001*** <0.0001*** 0.007** <0.0001*** <0.0001*** 0.03*
18 <0.0001*** 0.04* 0.1 <0.0001*** 0.01* 0.7
19 0.006** 0.008** 0.9 0.1 <0.0001*** 0.8
20 0.006** 0.6 0.2 0.02* 0.7 0.3
21 0.9 0.06 0.9 0.7 0.03* 0.6
22 0.1 0.6 0.7 0.4 0.3 0.9
23 0.2 0.4 0.7 0.9 0.3 0.9
24 0.1 0.9 0.7 0.4 0.9 0.6
25 0.9 0.9 0.5 0.9 0.9 0.2
P-values denote the tail area in a two-tailed Wald statistic (z value) test for the hypothesis that the associated model coefficient is 0 (and hence is unimportant when using that 
follicle diameter to predict number of oocytes and mature oocytes). Hence, a significantly important follicle diameter is expected to have a significantly low P-value. Follicle diameter 
significance levels are labeled *P < 0.05, **P < 0.01, and ***P < 0.001.
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significant difference in the total number of follicles in the one 
group compared with the other group (20.9 follicles vs 19.3 fol-
licles, P = 0.17) to account for this difference.
Repeating this analysis comparing patients with the 
upper tertile for proportion of their follicles within the range 
12–19 mm with the lowest tertile revealed an increase in the 
number of oocytes of 5.4 oocytes and 4.7 mature oocytes 
(P < 0.0001) for hCG and 4.8 oocytes and 4.9 mature oocytes 
(P <  0.01) for GnRHa triggering. For GnRHa, there was no 
significant difference in the total number of follicles in each 
tertile (20.5 vs 19.1, P = 0.16), but in the hCG group there was 
an increase of 1.7 more follicles on the day of trigger between 
Table 5 | Model importance factors (random forest) for follicle diameter in determining number of embryos and number of high quality embryos.
Follicle diameter 
(mm)
hcg gnrh agonist (gnrha) Kisspeptin hcg gnrha Kisspeptin
embryos grade 1 embryos
Model importance 
factor
Model importance  
factor
Model importance 
factor
Model importance  
factor
Model importance 
factor
Model importance 
factor
8 19.9 0.6 195.0 31.6 0.5 238.8
9 47.6 0.4 144.2 26.1 0.5 164.2
10 53.8 47.8 74.1 161.7 48.3 83.7
11 51.3 51.9 71.9 67.0 50.7 69.4
12 130.3 166.2 80.2 106.2 160.9 112.6
13 136.5 89.3 160.5 87.1 93.0 154.4
14 197.9 354.1 121.4 244.2 352.5 204.2
15 167.1 320.0 67.9 132.1 319.0 77.2
16 221.2 180.0 394.5 191.9 184.8 235.0
17 235.1 232.1 177.1 146.7 233.9 151.2
18 180.3 172.5 57.3 211.4 176.6 66.2
19 79.8 80.6 50.5 111.2 78.9 48.3
20 151.6 51.1 43.6 138.3 49.8 51.7
21 88.3 39.7 27.2 78.0 36.5 23.7
22 29.7 11.9 34.6 53.3 12.1 39.4
23 5.5 1.7 21.0 7.6 1.6 22.5
24 4.1 0.0 17.8 5.7 0.0 23.8
25 0.0 0.0 19.0 0.0 0.0 21.3
Model importance factors are the increases in node purity given by each follicle diameter averaged over 5,000 classification trees, each derived using bootstrap samples from the 
study data. Values over 100 (in bold) denote follicle diameters that are consistently important as predictors across multiple models, and hence strengthen the P-value results given in 
Table 4 which could result from a chance configuration of the study data.
Table 4 | Generalized linear model—number of embryos and number of high grade embryos.
Follicle diameter (mm) hcg gnrh agonist (gnrha) Kisspeptin hcg gnrha Kisspeptin
embryos grade 1 embryos
P-value P-value P-value P-value P-value P-value
8 0.67 0.3 0.05* 0.3 0.9 0.2
9 0.2 0.8 0.005* 0.5 0.8 0.04*
10 0.1 0.02* 0.3 0.1 0.2 0.8
11 0.8 0.3 0.9 0.7 0.9 0.9
12 0.8 0.02* 0.2 0.2 0.3 0.2
13 0.1 0.0004*** 0.6 0.1 0.2 0.3
14 0.001** <0.0001*** 0.6 0.6 0.002** 0.2
15 0.03* <0.0001*** 0.9 0.1 0.5 0.9
16 <0.0001*** <0.0001*** 0.3 0.6 0.06 0.5
17 0.01* <0.0001*** 0.09 0.8 0.06 0.1
18 0.006** 0.01* 0.7 0.9 0.09 0.7
19 0.5 0.04* 0.7 0.2 0.01* 0.9
20 0.007** 0.3 0.3 0.5 0.8 0.2
21 0.3 0.2 0.6 0.6 0.6 0.4
22 0.4 0.7 0.3 0.5 0.4 0.6
23 0.9 0.04* 0.5 0.8 0.6 0.5
24 0.3 0.9 0.5 0.8 0.9 0.2
25 0.9 0.9 0.5 0.9 0.9 0.5
P-values denote the tail area in a two-tailed Wald statistic (z value) test for the hypothesis that the associated model coefficient is 0 (and hence is unimportant when using that follicle 
diameter to predict number of embryos and Grade 1 embryos). Hence, a significantly important follicle diameter is expected to have a significantly low P-value. Follicle diameter 
significance levels are labeled *P < 0.05, **P < 0.01, and ***P < 0.001.
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the tertiles (15.1 vs 13.4; P <  0.01). While this is a potential 
confounder, this would be insufficient to explain the magnitude 
of increase observed.
Similarly, the number of oocytes, mature oocytes, and zygotes, 
was greater by the proportion of follicles within the follicles size 
range 12–19  mm on day of trigger for patients triggered with 
either hCG or GnRHa (see Figure  1). Furthermore, delaying 
triggering could result in more follicles > 19 mm which in turn 
could increase the risk of premature rise in serum progesterone 
(see Figure 2).
FigUre 1 | Scattergram (median and interquartile range) of the number of oocytes (a), mature oocytes (b), and zygotes (c) by the proportion of follicles on the day 
of trigger within the size range 12–19 mm in patients triggered with either hCG or GnRH agonist. Groups are compared by the Kruskal–Wallis test with post hoc 
Dunn’s correction for multiple comparisons (*P < 0.05 and ****P < 0.0001).
FigUre 2 | Scattergram (median and interquartile range) of serum 
progesterone (nmol/l) just prior to trigger administration by the number of 
follicles >19 mm on the day of kisspeptin trigger administration.
7
Abbara et al. Follicle Size Prior to Trigger
Frontiers in Endocrinology | www.frontiersin.org April 2018 | Volume 9 | Article 193
comparison of simulated Patients to 
Determine the expected importance of 
Follicle size on the number of Oocytes 
retrieved Following Trigger
Using the model generated through random forest analysis 
of patients triggered with hCG or GnRHa, we simulated 1,000 
patients having all their follicles within the optimal follicle 
size range (12–19 mm) and compared these to a further 1,000 
simulated patients with all their follicles outside of this size range. 
Our model predicts that the number of oocytes retrieved from 
patients with 20 follicles on the day of trigger would increase from 
a mean of 9.8 (95% prediction limit 9.3–10.3) to 14.8 (95% predic-
tion limit 13.3–16.3) oocytes due to the difference in follicle size 
profile alone (P < 0.001).
DiscUssiOn
It is widely accepted that the maturity and competence of oocytes 
change with the size of follicles during controlled ovarian stimu-
lation (1). Follicles that are either “too small” or “too large” are less 
likely to yield mature oocytes (1). To date, the size of follicles that 
are most likely to yield mature oocytes has predominantly been 
investigated on the day of oocyte retrieval (2, 18–22). Rosen et al. 
observed that the odds of retrieving mature oocytes from follicles 
of 13–15 mm on the day of oocyte retrieval were 70% less com-
pared with follicles > 18 mm (23). Wittmaack et al. observed that 
follicles with a volume < 1 ml (~12.4 mm) and >7 ml (~23.7 mm) 
had a statistically lower oocyte yield (59%) when compared with 
those between 1 and 7 ml (~74–85%) (21). Dubey et al. observed 
that fertilization rates are increased in oocytes from larger follicles 
on the day of oocyte retrieval (57.9% from 10 to 14 mm follicles, 
69.9% from 16 to 22 mm follicles, 73.9% from 22 to 26 mm fol-
licles) (22). However, Ectors et al. (2) observed that follicles of 
16–23 mm on the day of oocyte retrieval had higher fertilization 
rates (68%) than either follicles < 16 mm (56%) or those >23 mm 
(56%) (2). In that study, oocyte maturation rate rose from 75.3% 
from follicles < 16 mm, to 85.9% of follicles 16–23 mm, to 95.3% 
of follicle size > 23 mm (2). Overall, follicles of 16–22 mm on the 
day of oocyte retrieval are more likely to contain mature oocytes 
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than smaller follicles, while larger follicles are more likely to 
contain post-mature oocytes (1). However, limited data exist to 
establish which follicle size on the day of trigger is most likely to 
yield a mature oocyte.
In most centers, triggering is administered once two to three 
ovarian follicles are at least 17–18  mm in diameter. Therefore, 
ultrasound folliculograms used to determine the size of follicles 
on the morning of trigger are usually carried out 2  days prior 
to those used to determine the size of follicles on the day of 
oocyte retrieval. As follicles grow ~1.7 mm per day, follicle sizes 
presented in this study would be expected to be ~3–4 mm smaller 
than comparable studies assessing follicular sizes on the day of 
oocyte retrieval (1, 24). We determine that follicles of 12–19 mm 
on the day of trigger administration had the greatest contribution 
to the number of oocytes retrieved. This is consistent with the 
current literature which suggests that follicles of sizes 16–22 mm 
on the day of oocyte retrieval (measured 2 days later) contribute 
the most to the number of oocytes retrieved (1).
Some studies of follicle size on the day of oocyte retrieval have 
suggested that there are differences in fertilization rates or oocyte 
competence with follicle size (22, 25). Thus, one could hypothesize 
that while all follicles of sizes between 12 and 19 mm contributed 
to the number of oocytes retrieved, perhaps only oocytes derived 
from larger follicles in this range (e.g., 16–19 mm) would contrib-
ute to the number of zygotes and embryos formed. However, our 
analyses suggested that the sizes of follicles that contributed to the 
formation of embryos and high quality embryos were comparable 
to those contributing to oocytes and mature oocytes (see Tables 4 
and 5).
As this study was a non-interventional analysis and trigger-
ing was carried out once two to three ovarian follicles reached 
≥17–18 mm in diameter as per routine unit protocols, there were 
fewer follicles at larger sizes in this study. This was consistent 
with the work of Dubey and colleagues, whereby 85% of oocytes 
were collected from follicles of 14–24 mm at the time of oocyte 
retrieval (22). Consequently, we investigated whether patients 
having a greater proportion of their follicles within the size range 
12–19  mm on the day of trigger were likely to retrieve more 
oocytes than patients with the smallest proportion of follicles 
within this follicles size range. We observed that the tertile of 
patients with the highest proportion of oocytes within this size 
range on the day of trigger, retrieved ~50% more oocytes than 
patients with the lowest proportion of their follicles within this 
range. Importantly, this was not sufficiently explained by differ-
ences in the total number of follicles on the day of trigger.
As follicles increase beyond a certain size, they are more likely 
to yield post-mature oocytes. Furthermore, delaying triggering 
until follicles grow to a larger size could also result in an untimely 
rise in serum progesterone that could prematurely mature the 
endometrium, resulting in an out of phase endometrium and 
reduced implantation rates (26). In this study, we observe that 
pre-trigger serum progesterone was more likely to be elevated 
if there were a greater number of larger follicles (≥19 mm) on 
the day of trigger (see Figure  2). One could speculate that in 
addition to the size of follicles, the duration at which larger 
follicles are present before trigger administration and whether 
effective GnRH antagonism has been achieved could also 
contribute to the degree of premature progesterone elevation. 
Similarly, Kolibianakis observed that delaying the trigger by 
48 h resulted in 1.3 fewer follicles of 11–14 mm and 3.1 more 
follicles of ≥17 mm with an associated rise in progesterone of 
0.4 ng/ml and detrimental effects on pregnancy potential (27). 
Kyrou et al. compared administering the trigger once three fol-
licles were ≥16 mm in diameter (early), or 24 h later (late), and 
found that delaying triggering increased the number of mature 
oocytes retrieved (early 6.1, late 9.2, P = 0.009) with an associ-
ated rise in serum progesterone levels by 0.3 ng/ml (28). Mochtar 
and colleagues randomized women to receive trigger once the 
lead follicle was either 18 or 22  mm, and observed that those 
with a lead follicle of 22 mm had a greater number of follicles 
of 20–22 mm on day of trigger (3.95 vs 0.02) and an increase 
in two oocytes retrieved (29). Conversely, Tan and colleagues 
randomized patients to trigger either once the lead follicle was 
18 mm, or 1 day later, or 2 days later and observed no differences 
in the number of oocytes retrieved (30). Similarly, Tremellen 
and Lane found that patients with “ideal” timing of the hCG 
trigger (defined as ≥2 follicles of ≥17  mm, with the majority 
of follicles ≥14 mm) had similar outcomes to patients triggered 
either a day earlier or later (31), whereas Vandekerckhove et al. 
observed that a 24 h delay in trigger administration of patients 
with ≥3 follicles of ≥18 mm (and 30–50% of follicles ≥10 mm 
were also ≥1  8  mm) increased the number of mature oocytes 
retrieved by 2.4, but only in patients with a serum progesterone 
≤1 ng/ml (32). A meta-analysis by Chen et al. including 7 RCTs 
and 1,295 IVF cycles compared administration of hCG as soon 
as ≥3 follicles were ≥17 mm in size (“early”) vs administration 
of hCG either 24 or 48 h later (“late”) (33). While fertilization 
rates were higher in the 48 h later group (P < 0.0001), this result 
was predominantly attributable to the results of one study, and 
overall there was no significant benefit from later triggering (33).
Lessons on the size of follicle from which mature oocytes can 
be retrieved can also be learned from studies of in vitro maturation 
(IVM) (34). Follicles as small as 4 mm have been found to con-
tain mature oocytes, and mature oocytes from follicles ≤10 mm 
following hCG priming resulted in similar outcomes compared 
with those retrieved from larger follicles (35). However, the rate 
of in vivo matured oocytes positively correlated with follicle size 
(dominant follicle ≤10  mm 6.9%, 10–14  mm 10.6%, >14  mm 
15.1%) (36). Finally, Triwitayakorn et  al. observed that oocyte 
recovery rate increased from 57% of follicles < 10 mm to 80% of 
follicles 10–14 mm and further to 86% of follicles > 14 mm on 
the day of oocyte retrieval (37).
Kisspeptin has only recently been investigated as a trigger of 
oocyte maturation since 2014; consequently, data from the kiss-
peptin trials may have incorporated doses which were suboptimal 
for oocyte maturation. Thus, while similar results were observed 
for kisspeptin as for other triggers, it is interesting to note that 
some smaller follicles could also contribute to the number of 
oocytes retrieved for kisspeptin more so than for other triggers 
(see Tables 2 and 3). Although the contribution was small, sev-
eral studies have suggested that kisspeptin may have additional 
direct ovarian effects via ovarian kisspeptin receptors, beyond its 
predominant mode of action via endogenous GnRH release from 
the hypothalamus (38–41). Commensurate with this, Castellano 
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observed that kisspeptin expression increased in a cyclical man-
ner during the menstrual cycle of a rodent model, predominantly 
localized to the theca layer of growing follicles and the corpora 
lutea (38). Ovarian kisspeptin expression was undetectable in 
immature oocytes, but increased at ovulation (38). Kisspeptin has 
been reported to enhance IVM of sheep oocytes (39) and also of 
porcine oocytes, as well as blastocyst formation rate and blasto-
cyst hatching (40). However, while it is possible to speculate that 
kisspeptin could enhance oocyte maturation in combination with 
gonadotropin exposure, it is unlikely that in vivo administration 
can lead to oocyte maturation in the absence of a gonadotropin-
response (9).
Although the present study included patients with a large 
number of oocytes retrieved, we do not advocate the use of 
an hCG trigger in the high risk patient with multiple follicles, 
especially if fresh embryo transfer is intended to be carried out, 
and we definitely promote the use of GnRHa trigger for oocyte 
donation cycles. Limitations of the study include that is a non-
interventional retrospective analysis. Further randomized studies 
are required to determine whether triggering of oocyte maturation 
once most follicles are within the size range 12–19 mm can lead to 
improved oocyte yields compared with traditional determination 
of day of triggering. Furthermore, as data from hCG and GnRHa 
trigger were obtained from cycles without fresh embryo transfer, 
it was not possible to assess the reproductive potential of oocytes 
obtained from follicles of different sizes. The current method 
of determining the day of trigger administration once two to 
three lead follicles are 17–18 mm in size should lead to a similar 
day of trigger as most follicles will still be within the size range 
12–19 mm. However, determining the day of trigger based on the 
proportion of follicles within the size range 12–19 mm could be of 
particular value to patients with a wider spread of follicles behind 
the lead follicle. In addition, we recommend that these analyses 
be re-conducted in data sets obtained from different centers with 
the possibility of different stimulation protocols or study popula-
tions to confirm the results from this study.
In summary, we conclude that follicles of 12–19 mm on the 
day of trigger are most likely to yield mature oocytes on the day 
of oocyte retrieval. Thus, we recommend the reporting of mature 
oocyte yields using a denominator of follicle size of 12–19 mm 
on the day of trigger for studies investigating trigger efficacy. 
Future interventional studies should investigate whether using 
the proportion of follicles within 12–19 mm to determine the day 
of trigger administration could improve the number of mature 
oocytes retrieved.
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